News - Page 40 - Psychedelic Alpha

Read more about the article Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Post published:June 2, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in Upcoming June Investor Conferences

atai Life Sciences to Participate in Upcoming June Investor Conferences

Post published:June 1, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Post published:June 1, 2023
Post category:Press Release

Read more about the article State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

Post published:May 31, 2023
Post category:News

Read more about the article Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Post published:May 31, 2023
Post category:Press Release

Read more about the article COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Post published:May 31, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Post published:May 30, 2023
Post category:Psychedelic Bulletin

Read more about the article Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Post published:May 30, 2023
Post category:Press Release

Read more about the article Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Post published:May 30, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Post published:May 30, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.